Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Vitreomacular Adhesion Including Macular Hole
Interventions
DRUG

Ocriplasmin

0.125 mg single intravitreal injection

OTHER

Sham injection

Sham injection

Trial Locations (25)

13224

Retina Vitrous Surgeons of CNY, Syracuse

19006

Mid Atlantic Retina, Huntingdon Valley

28210

Southeast Clinical Research, PA, Charlotte

33143

MedEye Associates, Miami

33880

Center for Retina and Macular Disease, Winter Haven

44130

Retina Associates of Cleveland, Cleveland

45242

Cincinnati Eye Institute, Cincinnati

48073

Associated Retinal Consultants, Royal Oak

64108

Sabates Eye Center Research, Kansas City

75231

Texas Retina Associates, Dallas

75701

Eye Care Associate, Tyler

76012

Texas Retina Associates, Arlington

76104

Retina Consultants, PA, Fort Worth

77030

Vitroretinal Consultants, Houston

78240

Retina Consultants of San Antonio, San Antonio

78503

Valley Retina Institute, P.A., McAllen

78705

Retina Research Center, Austin

85014

Retinal Consultants of Arizona, Phoenix

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

94107

West Coast Retina Group, Inc, San Francisco

94598

Bay Area Retina Associates, Walnut Creek

95819

Retina Consultants Medical Group, Sacramento

03801

Eyesite Opthalmic Services, PA, Portsmouth

08901

Retina-Vitreous Center, PA, New Brunswick

07666

Retina Association of NJ, Teaneck

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ThromboGenics

INDUSTRY

NCT01429441 - Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole | Biotech Hunter | Biotech Hunter